CD24 hFc Chimera, Cynomolgus
CD24 HFc Chimera, Cynomolgus

The purity of CD24 hFc Chimera, Cynomolgus is greater than 95% as determined by SEC-HPLC.

CD24 HFc Chimera, Cynomolgus

CD24 hFc Chimera, Cynomolgus on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.

CD24 hFc Chimera, Cynomolgus

CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers.
Z04110
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
CD24 (Thr27-Lys54)
Accession # I7GKK1-1		 hFc
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 30.2 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 45-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • CD24 HFc Chimera, Cynomolgus
    • CD24 HFc Chimera, Cynomolgus

    The purity of CD24 hFc Chimera, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • CD24 HFc Chimera, Cynomolgus
    • CD24 HFc Chimera, Cynomolgus

    CD24 hFc Chimera, Cynomolgus on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.


Background
Target Background CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers.
Synonyms CD 24; CD24 molecule; CD24A; FLJ22950; FLJ43543; MGC75043

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.